"Conclusion: Gefitinib, administered in combination
with paclitaxel and carboplatin, provides a good clinical response but
associated with an increased risk of hematologic disorders."
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.